PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs
22.4.2021 17:44:00 EEST | Business Wire | Press release
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology, and global pharmaceutical companies based in Frankfurt’s Rhine-Main region.
The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (such as E3 ligases) so that they can be marked for destruction and recycled by the cells’ natural shredding capabilities.
To help in these efforts, PerkinElmer will provide the consortium with no-wash AlphaLISA® and HTRF® immunoassay technologies and expertise in protein labeling as well as assay design; EnVision ® multimode plate readers; high content imaging technologies such as the Opera Phenix ® and Operetta CLS™ platforms; and data analysis and informatics tools like TIBCO Spotfire ® software. These PerkinElmer offerings will give PROXIDRUGS scientists a highly sensitive and accelerated discovery platform with rich data delivery and high throughput for both live and dead cell research.
Commenting on this groundbreaking research and collaboration, Alan Fletcher, SVP of Life Sciences at PerkinElmer said, “With only 20% of disease-relevant proteins currently being targeted by classical, small molecule drugs, new research approaches, such as PROTAC drug discovery, hold immense and exciting potential. We are delighted to be able to contribute our expertise and technologies to assist in the innovative work of the PROXIDRUGS Consortium as it seeks new ways to help unlock and tackle the vast majority of proteins behind widespread diseases such as cancer, neurological disorders, and cardiovascular, inflammatory and infectious conditions.”
The PROXIDRUGS consortium is led by Ivan Đikić of Goethe University Frankfurt, who also commented on the importance of forming alliances across organizations to help advance novel drug discovery and development: “Successful translation of biomedical research requires strong collaboration and convergence of industry and academic expertise. Our work with PerkinElmer within the PROXIDRUGS consortium is a good example of that. PerkinElmer’s expertise and innovation in assay development is of utmost importance and will help to create new insights for our discovery efforts.”
The PROXIDRUGS Consortium was recently selected for funding by the German Federal Ministry of Education and Research as part of a highly competitive “Clusters4Future” competition.
For more information please visit:
https://www.perkinelmer.com/category/drug-discovery-screening-solutions and https://aktuelles.uni-frankfurt.de/englisch/proxidrugs-project-led-by-goethe-university-included-in-clusters4future-programme/.
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005766/en/
Contact information
Jennifer McNeil
jennifer.mcneil@perkinelmer.com
+1 508.380.2902
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 14:30:00 EEST | Press release
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise. The transaction is subject to customary closing conditions,
Organigram Reports Record Third Quarter Fiscal 2026 Results11.8.2026 13:00:00 EEST | Press release
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”). Q3 FISCAL 2026 HIGHLIGHTS Gross Revenue: $145.1 million (+32% year-over-year). Net Revenue: $105.8 million (+49% year-over-year). Adjusted EBITDA1: $13.4 million (+136% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #4 in beverages2. Sanity Group: Since the acquisition closed on April 15, 2026, Sanity has performed in line with management's expectations, contributing approximately €25 million (C$40 million) in net revenue to Organigram's consolidated results. During the quarter, Sanity continued to execute on its European growth strategy, advancing pr
L&T Technology Services Launches AgenticIQ™, an End-to-End Agentic AI Platform for Engineering, Manufacturing and Customer Experience11.8.2026 12:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of AgenticIQ™, an end-to-end Agentic AI platform purpose-built for engineering and manufacturing organizations. Designed to help enterprises move beyond isolated AI pilots, AgenticIQ™ enables autonomous, multi-agent workflows across engineering, product development, manufacturing, industrial operations and customer experience, accelerating the adoption of Engineering Intelligence at scale. As enterprises increase investments in AI, many initiatives continue to struggle to move beyond proof-of-concepts into production. Disconnected engineering systems, manual processes and highly regulated environments often prevent organizations from scaling autonomous AI while maintaining governance, security and operational reliability. Built on LTTS' portfolio of Engineering Intelligence solutions, AgenticIQ™ transforms proven engineering capa
Naser Taher Named Among Forbes Middle East’s Top 100 CEOs 202611.8.2026 12:00:00 EEST | Press release
MultiBank Group, one of the world’s largest and most regulated financial derivatives institutions, has announced that its Founder and Chairman, Naser Taher, has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811229836/en/ Naser Taher has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. The annual Forbes Middle East Top 100 CEOs list celebrates prominent business leaders who are shaping the region’s corporate landscape and leading organisations with significant scale, influence and impact. The ranking brings together senior executives from across key industries in the Middle East, highlighting their leadership and the performance and development of the organisati
teamLab Unveils New Series from Light Sculpture - Flow at teamLab Borderless. Special Exhibit, "On the Asymmetry of the Universe," on View Through October 811.8.2026 12:00:00 EEST | Press release
teamLab reopens the Light Sculpture - Flow series artwork space at teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Azabudai Hills, Tokyo from July 8, 2026. To commemorate the reopening, teamLab unveils two new series, Asymmetric Existence and Chromatic Existence, featured in the special exhibit "On the Asymmetry of the Universe." The special exhibit, “On the Asymmetry of the Universe,” runs from Wednesday, July 8, 2026 through Thursday, October 8, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807256066/en/ Light Sculpture - Flow The inside and outside of an ocean vortex are composed of the same water; there is no material difference between them. Yet, despite this, why do we perceive a vortex as a singular entity, or even sense a form of life within it? The difference between the inside and outside of a vortex lies in the order, not the material. When order is born within a flow, existence emerges even with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom